AG-86893 is a topical ocular eye drop reformulation of a marketed oral drug, a multi-tyrosine kinase inhibitor targeting several growth factor receptors such as VEGF, PDGF and FGF. AG-86893 is being developed for the treatment of pterygium, following a 505(B)(2) pathway.
AG-86893 is currently recruiting patients for a Phase 2a clinical trial called SURPH (a StUdy of the Response to AG-86893 in patients with Pterygium Hyperemia; NCT03533244). The SURPH trial is a multicenter, randomized, double-masked, vehicle-controlled study to evaluate the safety and tolerability of AG-86893 eye drops given three times daily for 28 days in patients with pterygium. In addition, the effect of AG-86893 on reducing ocular hyperemia will be assessed.
This trial is being conducted at 7 sites in Australia. Approximately 60-70 patients will be enrolled into three dose groups (vehicle, 0.1%, and 0.3% AG-86893). If you or a loved one has pterygium and would like to learn more about the SURPH Trial, and whether a study is near you, click HERE.